These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32560485)

  • 21. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
    Leung W; Kvizhinadze G; Nair N; Blakely T
    PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant trastuzumab chemotherapy in early breast cancer: meta-analysis of randomised trials and cost-effectiveness analysis.
    Doan TN; Barendregt J
    Swiss Med Wkly; 2019 May; 149():w20082. PubMed ID: 31104310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
    Nguyen AQ; Tran OTM; Nguyen PK; Nguyen HT
    PLoS One; 2024; 19(3):e0300474. PubMed ID: 38489305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States.
    Peng Y; Wang L; Peng L; Liu Q; Yi L; Luo X; Li S; Qin S; Wan X; Tan C; Chen G
    Clin Ther; 2023 Oct; 45(10):965-972. PubMed ID: 37537015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka.
    Gunasekara ADM; Youngkong S; Anothaisintawee T; Dejthevaporn T; Fernandopulle R; Chaikledkaew U
    Sci Rep; 2024 Jul; 14(1):16736. PubMed ID: 39033229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.
    Lidgren M; Jönsson B; Rehnberg C; Willking N; Bergh J
    Ann Oncol; 2008 Mar; 19(3):487-95. PubMed ID: 18065409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer.
    Konishi T; Fujiogi M; Michihata N; Ohbe H; Matsui H; Fushimi K; Tanabe M; Seto Y; Yasunaga H
    Jpn J Clin Oncol; 2022 Oct; 52(10):1115-1123. PubMed ID: 35775313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.
    Aboutorabi A; Hadian M; Ghaderi H; Salehi M; Ghiasipour M
    Glob J Health Sci; 2014 Aug; 7(1):98-106. PubMed ID: 25560346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States.
    Sussell J; Singh Jhuti G; Antao V; Herrera-Restrepo O; Wehler E; Bilir SP
    Am J Clin Oncol; 2021 Jul; 44(7):340-349. PubMed ID: 34151896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.
    Hedden L; O'Reilly S; Lohrisch C; Chia S; Speers C; Kovacic L; Taylor S; Peacock S
    Oncologist; 2012; 17(2):164-71. PubMed ID: 22302231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China.
    Deng W; Hu J; Li M; Yang S; Xie Z; Chen J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1117-1126. PubMed ID: 35899310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand.
    Kongsakon R; Lochid-Amnuay S; Kapol N; Pattanaprateep O
    Value Health Reg Issues; 2019 May; 18():47-53. PubMed ID: 30428405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.
    Chan AL; Leung HW; Lu CL; Lin SJ
    Ann Pharmacother; 2009 Feb; 43(2):296-303. PubMed ID: 19193576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
    Dai WF; Beca JM; Nagamuthu C; Liu N; de Oliveira C; Earle CC; Trudeau M; Chan KKW
    JAMA Oncol; 2022 Apr; 8(4):597-606. PubMed ID: 35201264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
    Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G
    JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review.
    Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):613-629. PubMed ID: 38738869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
    Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
    J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.